As you may have noticed, we have been on “Yaz” watch for the past several weeks. With the recent (and building) evidence that this popular birth control pill carries an increased risk of blood clotting, it’s become clear that this drug is not only dangerous, but potentially deadly. We have also blogged extensively about the side effects and injuries that have resulted from the drug.
Recently, an ABC news story about a pediatric nurse named Carissa Ubersox brought the Yaz dangers to the public forefront. Ubersox is reported to have nearly died after taking Yaz, which was sold by Bayer as a “miracle” drug for its supposed ability to treat acne and symptoms of Premenstrual Syndrome (PMS).
Much as also been made about the manner that Bayer went about advertising for the drug. The slogan, “beyond birth control,” represented the claims of treatment of acne, cramps and other PMS symptoms (of which the company was eventually forced to admit it didn’t actually have any effect on).
Beginning in 2009, the FDA began looking further into Yaz and took the unusual step of ordering Bayer to run corrective TV ads on Yaz to say that the drugmaker’s initial marketing claims were severely overstated.
We know that all birth control carries some small risk of blood clotting, but Bayer’s drug Yaz appears to carry a dramatically larger risk. After Bayer’s own, independent studies showed no additional risk, multiple new studies beg to differ. As a prominent Boston University School of Medicine professor explains in the “Nightline” report, “two Bayer studies found no increase in risk, while the four independent studies all found increased risk.”
Birth-control pills that contain drospirenone include Bayer’s Yaz, Yasmin, Beyaz, Safyral; Sandoz’s Syeda and Loryna; as well as Barr Laboratories’ Ocella, Watson Pharmaceuticals’ Zarah and Teva Pharmaceuticals’ Loryna.